Loxoribine is a selective agonist for TLR7 (Toll-like receptor 7) via IFN. Activates natural killer cells and primes cytolytic precursor cells for activation by IL-2. Loxoribine is a very potent immunostimulatory compound that increases cytokine production and possesses antitumor and antiviral properties.
Loxoribine (7-allyl-8-oxoguanosine) activates natural killer cells and primes cytolytic precursor cells for activation by IL-2: B.L. Pope, et al.; J. Immunol. 151, 3007 (1993) Loxoribine induces chronic lymphocytic leukemia B cells to traverse the cell cycle: M.G. Goodman, et al.; Blood 84, 3457 (1994) Three NF-kappa B binding sites in the human E-selectin gene required for maximal tumor necrosis factor alpha-induced expression: U. Schindler and V.R. Baichwal; Mol. Cell. Biol. 14, 5820 (1994) The immunostimulatory compound 7-allyl-8-oxoguanosine (loxoribine) induces a distinct subset of murine cytokines: B.L. Pope, et al.; Cell. Immunol. 162, 333 (1995) Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7: J. Lee, et al.; PNAS 100, 6646 (2003) Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN: I.B. Bekeredjian-Ding, et al.; J. Immunol. 174, 4043 (2005)
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.